How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/b-cell-precursor-acute-lymphoblastic-leukemia-all-that-is-refractory-or-in-second-or-later-relapse.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	Line of therapy	First approval
Kymriah	TISAGENLECLEUCEL	Novartis Pharmaceuticals Corporation	CD19-directed Chimeric Antigen Receptor [EPC]			2018-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Novartis Pharmaceuticals Corporation · 1 drug in B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse:

Cite this brief

Drug Landscape (2026). B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/b-cell-precursor-acute-lymphoblastic-leukemia-all-that-is-refractory-or-in-second-or-later-relapse. Accessed 2026-06-10.

B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing